Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
← catalyst calendarNCT07441876 · readout ≤ 1,046 d
Sponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
160estimated
Sites
19
Countries
Australia, Canada, Italy +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-20 | actual | When the study began enrolling |
| Primary completion | Jun 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Achondroplasia
Interventions
- Drug: BMN 333
- Drug: Vosoritide Injection [Voxzogo]
Primary outcomes
what the primary-completion date above is the date OFPhase 2: Predicted Annualized Growth Velocity (AGV) at Week 52 (based on AGV at Weeks 26, 39, and 52 [available cumulative data]
measured 52 weeks
Phase 3: Annualized Growth Velocity (AGV) at Week 52
measured 52 weeks
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed